Existing Customer

Renew your plan
Refer & Earn
HomeGreater Than Icon
Biofil Chemicals & Pharmaceuticals LtdGreater Than Icon
Biofil Chemicals & Pharmaceuticals Ltd Financials
Company Logo

Biofil Chemicals & Pharmaceuticals Ltd Financial Statement

Biofil Chemicals & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2024
Revenue15.61
Operating Expense15.24
Net Profit0.25
Net Profit Margin1.60
Earning Per Share0.15
EBIDTA0.46
Effective Tax Rate29.73

Biofil Chemicals & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual30.04
Operating Expenses Annual28.87
Operating Profit Annual1.26
Interest Annual0.04
Depreciation0.43
Net Profit Annual0.56
Tax Annual0.23

Biofil Chemicals & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the Beginning0.14
Cash Flow from Operations-0.11
Cash Flow from Investing-0.01
Cash Flow from Financing0.02
Cash Flow at the End0.04

Biofil Chemicals & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)4.19
PBIT Margin (%)2.76
PBT Margin (%)-66.31
Net PROFIT Margin (%)1.86
Return On Networth / Equity (%)1.12
Return On Networth /Employed (%)1.65
Return On Assets (%)3.19
Total Debt / Equity (X)0.03
Asset Turnover Ratio (%)1.71

Biofil Chemicals & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual9.00
Total Current Assets Annual22.41
Non Current Assets Annual9.00
Total Shareholders Funds Annual17.30
Total Assets Annual31.41

Biofil Chemicals & Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Jul 27, 2024, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 98.21 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Biofil Chemicals & Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.02.
In FY 2023 , Biofil Chemicals & Pharmaceuticals Ltd recorded a total revenue of approximately 40.04 Cr marking a significant milestone in the company's financial performance.
Biofil Chemicals & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.3% annually, respectively..
Biofil Chemicals & Pharmaceuticals Ltd's current PE ratio is 138.32.
Biofil Chemicals & Pharmaceuticals Ltd's ROCE averaged 5.2% from the FY ending March 2022 to 2024, with a median of 4.9%. It peaked at 6.1% in March 2022, reflecting strong capital efficiency over the period..
Biofil Chemicals & Pharmaceuticals Ltd's latest EBIT is Rs. 0.91 Cr, surpassing the average EBIT of Rs. 0.93 Cr over the 5 years..